4//SEC Filing
TriVascular Technologies, Inc. 4
Accession 0001562180-16-001509
CIK 0001432732operating
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 4:35 PM ET
Size
19.8 KB
Accession
0001562180-16-001509
Insider Transaction Report
Form 4
Kramer Michael R
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2016-02-03$5.62/sh−7,238$40,678→ 101,103 total - Disposition to Issuer
Common Stock
2016-02-03−92,309→ 0 total - Disposition to Issuer
Common Stock
2016-02-03−8,794→ 92,309 total - Exercise/Conversion
Common Stock
2016-02-03+15,000→ 107,309 total - Tax Payment
Common Stock
2016-02-03$5.62/sh−6,561$36,873→ 100,748 total - Disposition to Issuer
Common Stock
2016-02-03−8,439→ 92,309 total - Exercise/Conversion
Common Stock
2016-02-03$2.43/sh+16,032$38,958→ 108,341 total - Exercise/Conversion
Restricted Stock Units (RSU)
2016-02-03−15,000→ 0 total→ Common Stock (15,000 underlying) - Exercise/Conversion
Stock Options (Right to buy)
2016-02-03−16,032→ 0 totalExercise: $2.43Exp: 2020-10-05→ Common Stock (16,032 underlying)
Footnotes (7)
- [F1]Each RSU represents a contingent right to receive one share of TRIV common stock.
- [F2]This quantity includes 2,795 ESPP shares.
- [F3]These shares were withheld by the issuer to satisfy tax withholding obligations and calculated for the purposes of the deemed settlement of the RSUs, contingent upon the closing of the Merger (as defined below), utilizing the closing price of the issuers common stock on January 28, 2016.
- [F4]These shares were disposed of pursuant to the merger agreement between the issuer and Endologix, Inc. (such transaction, the Merger). In connection with the closing of the Merger, the reporting person received 0.6312 share of Endologix common stock and $0.34 in cash for each share of issuer common stock held by such reporting person, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016.
- [F5]These shares were withheld by the issuer as payment of the exercise price and to satisfy tax withholding obligations, and calculated for the purposes of the deemed exercise of the options, contingent upon the closing of the Merger, utilizing the closing price of the issuers common stock on January 28, 2016.
- [F6]These restricted stock units became 100% vested in connection with the Merger.
- [F7]These stock options became 100% vested in connection with the Merger.
Documents
Issuer
TriVascular Technologies, Inc.
CIK 0001432732
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001432732
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 4:35 PM ET
- Size
- 19.8 KB